DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
S-phase fraction (SPF) is a reference for cell-kinetic analysis. In this study, the links between SPF and the essential enzymes participating in the pyrimidine synthesis were investigated in breast cancer and their relationships with the natural history of the disease were compared. We measured thymidine kinase (TK) for salvage synthesis, thymidylate synthase (TS) for de novo synthesis and thymidylate kinase (TMK), which is required for both pathways. Our study population consisted of 211 premenopausal women with node-negative tumors. SPF was assessed prospectively by flow cytometry, whereas enzyme activities were measured retrospectively in cytosols using radioenzymatic methods. Among the enzymes analyzed, only TK demonstrated a strong correlation with SPF (r(s) = 0.59). In univariate analysis, high SPF and high levels of TK were associated with increased risk of developing distant recurrences (p < 0.001). Correlations with other prognostic factors (histological grade, steroid receptors, DNA ploidy status, urokinase plasminogen activator and plasminogen activator inhibitor type 1) confirmed a parallel association of SPF and TK with the most aggressive tumors. In contrast, TS and TMK were not associated with prognosis. After adjustment for SPF, the risk of relapse increased significantly with TK values. Subgroup analysis showed that additional information was provided by TK in the tumors with low SPF. When urokinase plasminogen activator (uPA) was a candidate variable in multivariate analysis, TK remained significant. Combined with SPF and uPA, TK could be useful to define premenopausal node-negative patients with rapidly proliferating tumors at a high risk of metastatic disease.
Laboratoire de Transfert d'Oncologie Biologique, Faculté de Médecine Nord, Marseilles, France. sromain@ap-hm.fr
S
S
Romain
P O
PO
Bendahl
O
O
Guirou
P
P
Malmström
P M
PM
Martin
M
M
Fernö
D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007700:Kinetics; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009703:Nucleoside-Phosphate Kinase / Q000096:biosynthesis*; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D017697:Premenopause; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D016196:S Phase; D013937:Thymidine Kinase / Q000096:biosynthesis*; D013940:Thymidylate Synthase / Q000096:biosynthesis*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis
D017395:Plasminogen Activator Inhibitor 1; D013940:Thymidylate Synthase; D013937:Thymidine Kinase; D009703:Nucleoside-Phosphate Kinase; C020093:dTMP kinase; D014568:Urokinase-Type Plasminogen Activator